Panagiotis Douvaras
Research Subjects
Panagiotis Douvaras has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Valentina Fossati
The New York Stem Cell Foundation Research Institute, New York, New York, USA
13 shared publications - John D. West
Genes and Development Group, Centre for Integrative Physiology, Clinical Sciences, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK
6 shared publications Robert E. Hill
Medical and Developmental Genetics Section, MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
5 shared publicationsRichard L. Mort
Genes and Development Group, Centre for Integrative Physiology, Clinical Sciences, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK
4 shared publications- Steven D. Morley
Edinburgh Medical School, The University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK
4 shared publications J. Martin Collinson
University of Aberdeen
2 shared publications
Latest Publications
- Open Access
- 23 October 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-10
Oligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenias implicate abnormalities in development
Abnormalities of brain connectivity and signal transduction are consistently observed in individuals with schizophrenias (SZ). Underlying these anomalies, convergent in vivo, post mortem, and genomic evidence suggest abnormal oligodendrocyte (OL) development and function and lower myelination in SZ. Our primary hypothesis was that there would be abnormalities in the number of induced pluripotent stem (iPS) cell-derived OLs from subjects with SZ. Our secondary hypothesis was that these in vitro abnormalities would correlate with measures of white matter (WM) integrity and myelination in the same subjects in vivo, estimated from magnetic resonance imaging. Six healthy control (HC) and six SZ iPS cell lines, derived from skin fibroblasts from well-characterized subjects, were differentiated into OLs. FACS analysis of the oligodendrocyte-specific surface, glycoprotein O4, was performed at three time points of development (days 65, 75, and 85) to quantify the number of late oligodendrocyte progenitor cells (OPCs) and OLs in each line. Significantly fewer O4-positive cells developed from SZ versus HC lines (95% CI 1.0: 8.6, F1,10 = 8.06, p = 0.02). The difference was greater when corrected for age (95% CI 5.4:10.4, F1,8 = 53.6, p < 0.001). A correlation between myelin content in WM in vivo, estimated by magnetization transfer ratio (MTR) and number of O4-positive cells in vitro was also observed across all time points (F1,9 = 4.3, p = 0.07), reaching significance for mature OLs at day 85 in culture (r = 0.70, p < 0.02). Low production of OPCs may be a contributing mechanism underlying WM reduction in SZ.
- 23 October 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-10
Open AccessOligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenias implicate abnormalities in development
Abnormalities of brain connectivity and signal transduction are consistently observed in individuals with schizophrenias (SZ). Underlying these anomalies, convergent in vivo, post mortem, and genomic evidence suggest abnormal oligodendrocyte (OL) development and function and lower myelination in SZ. Our primary hypothesis was that there would be abnormalities in the number of induced pluripotent stem (iPS) cell-derived OLs from subjects with SZ. Our secondary hypothesis was that these in vitro abnormalities would correlate with measures of white matter (WM) integrity and myelination in the same subjects in vivo, estimated from magnetic resonance imaging. Six healthy control (HC) and six SZ iPS cell lines, derived from skin fibroblasts from well-characterized subjects, were differentiated into OLs. FACS analysis of the oligodendrocyte-specific surface, glycoprotein O4, was performed at three time points of development (days 65, 75, and 85) to quantify the number of late oligodendrocyte progenitor cells (OPCs) and OLs in each line. Significantly fewer O4-positive cells developed from SZ versus HC lines (95% CI 1.0: 8.6, F1,10 = 8.06, p = 0.02). The difference was greater when corrected for age (95% CI 5.4:10.4, F1,8 = 53.6, p < 0.001). A correlation between myelin content in WM in vivo, estimated by magnetization transfer ratio (MTR) and number of O4-positive cells in vitro was also observed across all time points (F1,9 = 4.3, p = 0.07), reaching significance for mature OLs at day 85 in culture (r = 0.70, p < 0.02). Low production of OPCs may be a contributing mechanism underlying WM reduction in SZ.
- 1 August 2018
- Published by Elsevier in Cell Stem Cell
- Vol. 23 (2) , 239-251.e6
GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease
- 1 August 2018
- Published by Elsevier in Cell Stem Cell
- Vol. 23 (2) , 239-251.e6
GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease
- Top Cited Papers
- 25 July 2018
- Published by Springer Nature in Nature Methods
- Vol. 15 (9) , 700-706
Induction of myelinating oligodendrocytes in human cortical spheroids
Cerebral organoids provide an accessible system for investigations of cellular composition, interactions, and organization but have lacked oligodendrocytes, the myelinating glia of the central nervous system. Here we reproducibly generated oligodendrocytes and myelin in ‘oligocortical spheroids’ derived from human pluripotent stem cells. Molecular features consistent with those of maturing oligodendrocytes and early myelin appeared by week 20 in culture, with further maturation and myelin compaction evident by week 30. Promyelinating drugs enhanced the rate and extent of oligodendrocyte generation and myelination, and spheroids generated from human subjects with a genetic myelin disorder recapitulated human disease phenotypes. Oligocortical spheroids provide a versatile platform for studies of myelination of the developing central nervous system and offer new opportunities for disease modeling and therapeutic development.
- 25 July 2018
- Published by Springer Nature in Nature Methods
- Vol. 15 (9) , 700-706
Top Cited PapersInduction of myelinating oligodendrocytes in human cortical spheroids
Cerebral organoids provide an accessible system for investigations of cellular composition, interactions, and organization but have lacked oligodendrocytes, the myelinating glia of the central nervous system. Here we reproducibly generated oligodendrocytes and myelin in ‘oligocortical spheroids’ derived from human pluripotent stem cells. Molecular features consistent with those of maturing oligodendrocytes and early myelin appeared by week 20 in culture, with further maturation and myelin compaction evident by week 30. Promyelinating drugs enhanced the rate and extent of oligodendrocyte generation and myelination, and spheroids generated from human subjects with a genetic myelin disorder recapitulated human disease phenotypes. Oligocortical spheroids provide a versatile platform for studies of myelination of the developing central nervous system and offer new opportunities for disease modeling and therapeutic development.
- 23 October 2017
- Published by Wiley in Annals of Neurology
- Vol. 82 (5) , 795-812
Molecular‐based diagnosis of multiple sclerosis and its progressive stage
Objective: Biomarkers aid diagnosis, allow inexpensive screening of therapies, and guide selection of patient‐specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease‐modifying therapy without understanding patient‐specific drivers of disability. Therefore, using multiple sclerosis (MS) as an example of a complex polygenic neurological disease, we sought to determine whether cerebrospinal fluid (CSF) biomarkers are intraindividually stable, cell type‐, disease‐ and/or process‐specific, and responsive to therapeutic intervention.Methods: We used statistical learning in a modeling cohort (n = 225) to develop diagnostic classifiers from DNA‐aptamer–based measurements of 1,128 CSF proteins. An independent validation cohort (n = 85) assessed the reliability of derived classifiers. The biological interpretation resulted from in vitro modeling of primary or stem cell–derived human CNS cells and cell lines.Results: The classifier that differentiates MS from CNS diseases that mimic MS clinically, pathophysiologically, and on imaging achieved a validated area under the receiver operating characteristic curve (AUROC) of 0.98, whereas the classifier that differentiates relapsing–remitting from progressive MS achieved a validated AUROC of 0.91. No classifiers could differentiate primary progressive from secondary progressive MS better than random guessing. Treatment‐induced changes in biomarkers greatly exceeded intraindividual and technical variabilities of the assay.Interpretation: CNS biological processes reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific. This opens opportunities for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorders. Ann Neurol 2017;82:795–812
- 23 October 2017
- Published by Wiley in Annals of Neurology
- Vol. 82 (5) , 795-812
Molecular‐based diagnosis of multiple sclerosis and its progressive stage
Objective: Biomarkers aid diagnosis, allow inexpensive screening of therapies, and guide selection of patient‐specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease‐modifying therapy without understanding patient‐specific drivers of disability. Therefore, using multiple sclerosis (MS) as an example of a complex polygenic neurological disease, we sought to determine whether cerebrospinal fluid (CSF) biomarkers are intraindividually stable, cell type‐, disease‐ and/or process‐specific, and responsive to therapeutic intervention.Methods: We used statistical learning in a modeling cohort (n = 225) to develop diagnostic classifiers from DNA‐aptamer–based measurements of 1,128 CSF proteins. An independent validation cohort (n = 85) assessed the reliability of derived classifiers. The biological interpretation resulted from in vitro modeling of primary or stem cell–derived human CNS cells and cell lines.Results: The classifier that differentiates MS from CNS diseases that mimic MS clinically, pathophysiologically, and on imaging achieved a validated area under the receiver operating characteristic curve (AUROC) of 0.98, whereas the classifier that differentiates relapsing–remitting from progressive MS achieved a validated AUROC of 0.91. No classifiers could differentiate primary progressive from secondary progressive MS better than random guessing. Treatment‐induced changes in biomarkers greatly exceeded intraindividual and technical variabilities of the assay.Interpretation: CNS biological processes reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific. This opens opportunities for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorders. Ann Neurol 2017;82:795–812
- Top Cited PapersOpen Access
- 1 June 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (6) , 1516-1524
Directed Differentiation of Human Pluripotent Stem Cells to Microglia
- 1 June 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (6) , 1516-1524
Top Cited PapersOpen AccessDirected Differentiation of Human Pluripotent Stem Cells to Microglia
- 1 April 2017
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 100 (4) , 617-634
Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes
- 1 April 2017
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 100 (4) , 617-634
Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes
- 1 March 2017
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 43 (suppl_1) , S146
SA93. Deletion of CNTNAP2 and White Matter Changes in Schizophrenia
Background: Schizophrenia (SZ) is a severe mental disorder with heritability estimated at ~80%. Genetic variants in contactin-associated protein-like 2 (CNTNAP2) have been reported in SZ. This gene is critically involved in normal neuronal synchronization and myelin production. Deletions in this gene would therefore be expected to impact white matter (WM) integrity. Compromised WM integrity has been implicated in SZ and may also be a heritable biomarker. In order to help characterize the genetic components of WM changes in SZ, we examined 2 carriers of a large heterozygous deletion in CNTNAP2 with discordant clinical phenotypes. Methods: A 59-year-old female proband who met DSM-IV criteria for a diagnosis of schizoaffective disorder (depressed subtype), her clinically unaffected 90-year-old father, and 4 unrelated nonpsychiatric controls completed a diffusion kurtosis imaging protocol on a Siemens 3T system. Human-induced pluripotent stem cell (hiPSC) lines from skin biopsies of both carriers were generated and differentiated in vitro to oligodendrocytes. Results: The fractional anisotropy (FA) and radial kurtosis (RK) were reduced, and the radial diffusivity (RD) was increased in the corona radiata and the genu of the corpus callosum (CC) in the proband compared with the father and controls. The clinically unaffected father closely resembled the controls in the genu of CC but differed from them in the uncinate fasciculus and internal capsule. In the whole-brain WM analysis, the FA and RK were reduced, and the RD was increased, in both the proband and the father compared with the controls, more substantially in the proband than in the father. Preliminary results from the in vitro differentiation suggest defective differentiation of patient-derived hiPSCs to oligodendrocyte precursor cells in the proband only. Conclusion: These preliminary data suggest that WM integrity is compromised in both carriers, possibly due to a demyelinating process that may be associated with this specific mutation. More severe and widespread demyelination is present in the clinically affected proband than in the unaffected carrier father, suggesting that additional WM changes may be associated with SZ, possibly independent of this mutation. These findings complement the molecular and cellular phenotypes of the hiPSC neural cells derived from these carriers and support the role of brain imaging in helping to elucidate objectively measurable neuroanatomic phenotypic consequences of genetic variant susceptibility. This is one of the first studies to combine neuroimaging and hiPSC-based observations in carriers of the same mutation with discordant phenotypes, demonstrating the utility of both approaches in understanding pleiotropic clinical effects.
- 1 March 2017
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 43 (suppl_1) , S146
SA93. Deletion of CNTNAP2 and White Matter Changes in Schizophrenia
Background: Schizophrenia (SZ) is a severe mental disorder with heritability estimated at ~80%. Genetic variants in contactin-associated protein-like 2 (CNTNAP2) have been reported in SZ. This gene is critically involved in normal neuronal synchronization and myelin production. Deletions in this gene would therefore be expected to impact white matter (WM) integrity. Compromised WM integrity has been implicated in SZ and may also be a heritable biomarker. In order to help characterize the genetic components of WM changes in SZ, we examined 2 carriers of a large heterozygous deletion in CNTNAP2 with discordant clinical phenotypes. Methods: A 59-year-old female proband who met DSM-IV criteria for a diagnosis of schizoaffective disorder (depressed subtype), her clinically unaffected 90-year-old father, and 4 unrelated nonpsychiatric controls completed a diffusion kurtosis imaging protocol on a Siemens 3T system. Human-induced pluripotent stem cell (hiPSC) lines from skin biopsies of both carriers were generated and differentiated in vitro to oligodendrocytes. Results: The fractional anisotropy (FA) and radial kurtosis (RK) were reduced, and the radial diffusivity (RD) was increased in the corona radiata and the genu of the corpus callosum (CC) in the proband compared with the father and controls. The clinically unaffected father closely resembled the controls in the genu of CC but differed from them in the uncinate fasciculus and internal capsule. In the whole-brain WM analysis, the FA and RK were reduced, and the RD was increased, in both the proband and the father compared with the controls, more substantially in the proband than in the father. Preliminary results from the in vitro differentiation suggest defective differentiation of patient-derived hiPSCs to oligodendrocyte precursor cells in the proband only. Conclusion: These preliminary data suggest that WM integrity is compromised in both carriers, possibly due to a demyelinating process that may be associated with this specific mutation. More severe and widespread demyelination is present in the clinically affected proband than in the unaffected carrier father, suggesting that additional WM changes may be associated with SZ, possibly independent of this mutation. These findings complement the molecular and cellular phenotypes of the hiPSC neural cells derived from these carriers and support the role of brain imaging in helping to elucidate objectively measurable neuroanatomic phenotypic consequences of genetic variant susceptibility. This is one of the first studies to combine neuroimaging and hiPSC-based observations in carriers of the same mutation with discordant phenotypes, demonstrating the utility of both approaches in understanding pleiotropic clinical effects.
- Open Access
- 1 August 2016
- Published by Elsevier in Experimental Eye Research
- Vol. 149, 26-39
Abnormal corneal epithelial maintenance in mice heterozygous for the micropinna microphthalmia mutation Mp
- 1 August 2016
- Published by Elsevier in Experimental Eye Research
- Vol. 149, 26-39
Open AccessAbnormal corneal epithelial maintenance in mice heterozygous for the micropinna microphthalmia mutation Mp
- Open Access
- 22 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (4) , 614
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes
Pluripotent stem cells provide an invaluable tool for generating human, disease-relevant cells. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system, characterized by myelin damage. Oligodendrocytes are the myelinating cells of the central nervous system (CNS); they differentiate from progenitor cells, and their membranes ensheath axons, providing trophic support and allowing fast conduction velocity. The current understanding of oligodendrocyte biology was founded by rodent studies, where the establishment of repressive epigenetic marks on histone proteins, followed by activation of myelin genes, leads to lineage progression. To assess whether this epigenetic regulation is conserved across species, we differentiated human embryonic and induced pluripotent stem cells to oligodendrocytes and asked whether similar histone marks and relative enzymatic activities could be detected. The transcriptional levels of enzymes responsible for methylation and acetylation of histone marks were analyzed during oligodendrocyte differentiation, and the post-translational modifications on histones were detected using immunofluorescence. These studies showed that also in human cells, differentiation along the oligodendrocyte lineage is characterized by the acquisition of multiple repressive histone marks, including deacetylation of lysine residues on histone H3 and trimethylation of residues K9 and K27. These data suggest that the epigenetic modulation of oligodendrocyte identity is highly conserved across species.
- 22 April 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (4) , 614
Open AccessEpigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes
Pluripotent stem cells provide an invaluable tool for generating human, disease-relevant cells. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system, characterized by myelin damage. Oligodendrocytes are the myelinating cells of the central nervous system (CNS); they differentiate from progenitor cells, and their membranes ensheath axons, providing trophic support and allowing fast conduction velocity. The current understanding of oligodendrocyte biology was founded by rodent studies, where the establishment of repressive epigenetic marks on histone proteins, followed by activation of myelin genes, leads to lineage progression. To assess whether this epigenetic regulation is conserved across species, we differentiated human embryonic and induced pluripotent stem cells to oligodendrocytes and asked whether similar histone marks and relative enzymatic activities could be detected. The transcriptional levels of enzymes responsible for methylation and acetylation of histone marks were analyzed during oligodendrocyte differentiation, and the post-translational modifications on histones were detected using immunofluorescence. These studies showed that also in human cells, differentiation along the oligodendrocyte lineage is characterized by the acquisition of multiple repressive histone marks, including deacetylation of lysine residues on histone H3 and trimethylation of residues K9 and K27. These data suggest that the epigenetic modulation of oligodendrocyte identity is highly conserved across species.
- 2 July 2015
- Published by Springer Nature in Nature Protocols
- Vol. 10 (8) , 1143-1154
Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells
In the CNS, oligodendrocytes act as the myelinating cells. Oligodendrocytes have been identified to be key players in several neurodegenerative disorders. This protocol describes a robust, fast and reproducible differentiation protocol to generate human oligodendrocytes from pluripotent stem cells (PSCs) using a chemically defined, growth factor-rich medium. Within 8 d, PSCs differentiate into paired box 6-positive (PAX6(+)) neural stem cells, which give rise to OLIG2(+) progenitors by day 12. Oligodendrocyte lineage transcription factor 2-positive (OLIG2(+)) cells begin to express the transcription factor NKX2.2 around day 18, followed by SRY-box 10 (SOX10) around day 40. Oligodendrocyte progenitor cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+)) appear around day 50 and reach, on average, 43% of the cell population after 75 d of differentiation. O4(+) OPCs can be isolated by cell sorting for myelination studies, or they can be terminally differentiated to myelin basic protein-positive (MBP(+)) oligodendrocytes. This protocol also describes an alternative strategy for markedly reducing the length and the costs of the differentiation and generating ∼30% O4(+) cells after only 55 d of culture.
- 2 July 2015
- Published by Springer Nature in Nature Protocols
- Vol. 10 (8) , 1143-1154
Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells
In the CNS, oligodendrocytes act as the myelinating cells. Oligodendrocytes have been identified to be key players in several neurodegenerative disorders. This protocol describes a robust, fast and reproducible differentiation protocol to generate human oligodendrocytes from pluripotent stem cells (PSCs) using a chemically defined, growth factor-rich medium. Within 8 d, PSCs differentiate into paired box 6-positive (PAX6(+)) neural stem cells, which give rise to OLIG2(+) progenitors by day 12. Oligodendrocyte lineage transcription factor 2-positive (OLIG2(+)) cells begin to express the transcription factor NKX2.2 around day 18, followed by SRY-box 10 (SOX10) around day 40. Oligodendrocyte progenitor cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+)) appear around day 50 and reach, on average, 43% of the cell population after 75 d of differentiation. O4(+) OPCs can be isolated by cell sorting for myelination studies, or they can be terminally differentiated to myelin basic protein-positive (MBP(+)) oligodendrocytes. This protocol also describes an alternative strategy for markedly reducing the length and the costs of the differentiation and generating ∼30% O4(+) cells after only 55 d of culture.